通过药物诱导的布拉迪基宁介导的血管
Chiara Suffritti1, Samantha Chan2,3,4, Anne Lise Ferrara5,6
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.
Journal of clinical medicine
|August 28, 2025
概括
血管激素转化酶抑制剂 (ACEI) 和血管激素II受体阻断剂 (ARBs) 可能导致布拉迪基宁介导的血管 (AE). 本综述讨论了药物诱导的血管的机制,诊断和治疗的未满足需求以及治疗方法.
科学领域:
- 药理学
- 心血管医学
- 过敏和免疫学
背景情况:
- 血管激素转化酶抑制剂 (ACEI) 和血管激素II受体阻断剂 (ARB) 广泛用于预防心血管疾病.
- 这些药物可以诱导布拉迪基宁 (BK) 介导的血管 (AE),这是由血管透性增加引起的潜在致命的胀.
- 与遗传性血管 (HAE) 不同,药物诱导的AE缺乏已批准的诊断工具和治疗方法.
研究的目的:
- 审查药物诱导的BK介导血管的分子机制.
- 突出目前对这种药物不良反应的诊断和治疗的未满足需求.
- 为医生提供必要的知识,以了解和管理可能危及生命的药物诱导的AE.
主要方法:
- 关于药物诱导的血管的文献综述
- 讨论涉及布拉迪基宁的分子机制.
- 分析目前的诊断和治疗缺口.
主要成果:
- ACEI和ARB是BK介导的AE的常见原因.
- 其他药物,如DPP-IV抑制剂和 neprilysin抑制剂也可能导致AE.
- 关于AE预防和管理的数据不够.
结论:
- 药物诱导的血管是一种严重的不良反应,需要更好的理解和管理策略.
- 对于药物诱导的AE,急需获得批准的诊断工具和特定治疗方法.
- 进一步研究分子机制和预防至关重要.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Allergic Drug Reactions
972
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
972
Allergic Reactions
28.5K
Overview
28.5K
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817


